European Stocks Rise Ahead of ECB Rate Decision as Investors Buy the Dip 
Adobe Beats Q2 2026 Estimates, Raises Full-Year Outlook as AI Revenue Surges Despite Stock Drop 
Honda Leadership Crisis Deepens as Retired Executives Challenge CEO Toshihiro Mibe’s Strategy 
Alibaba Offers $1.5 Billion to Acquire Grocery Delivery Platform Pupu 
oOh!media Takeover Battle Intensifies as Bain Capital Joins Competing Bids 
ECB Set to Raise Interest Rates as Energy Shock Fuels Eurozone Inflation Concerns 
Asics Considers Onitsuka Tiger Spinoff as Luxury Sneaker Brand Expands Globally 
Frasers Group Launches €2 Billion Hugo Boss Takeover Offer Amid Control Speculation 
Meta AI Strategy Faces Challenges as Zuckerberg Admits Mistakes in Internal Memo 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Meta Partners With Reliance to Launch First AI-Powered Data Center in India 
Asian Stocks Slide as Tech Selloff Deepens and US-Iran Conflict Escalates 
Asian Currencies Mixed as Dollar Slips on Iran Peace Hopes and Fed Rate Outlook 
ECB Keeps July Rate Options Open Amid Iran War Energy Price Risks 
Exxon Mobil Set to Appoint Alex Volkov as Global Trading Chief 
Pakistan Economy Grows 3.7% in FY2026 Amid Strong Fiscal Performance 
OpenAI May Slash AI Service Prices Amid Growing Rivalry With Anthropic 
Abbott Nutrition said last weekend that it had reopened its Sturgis, Michigan plant to resume the production of baby formula. The company hopes that the nationwide shortage of milk will be addressed once it begins the normal production once again.
Abbott Nutrition was able to open its production facility in Michigan after the U.S. Food and Drug Administration (USFDA) had given it the go-ahead to do so. The permit was granted by the agency after the company met the initial requirements as part of a May 16 consent decree.
According to CNBC, Abbott Nutrition will now restart the production of its EleCare baby formula that has been formulated for children who have difficulties digesting other products. The company will also manufacture its other specialty milk and metabolic formulas for infants.
As the company is now able to begin production again, it is hoping to release the first batch of EleCare milk products by June 20. Currently, Abbott is still working to comply with the guidelines set for the resumption of production for its Similac milk line and other infant formulas.
“We understand the urgent need for formula and our top priority is getting high-quality, safe formula into the hands of families across America,” Abbott’s spokesman said in a statement. “We will ramp production as quickly as we can while meeting all requirements.“
It was noted that the issue with the supply of baby formula began in the early stage of the COVID-19 pandemic. However, the situation got worse when Abbott Nutrition’s production facility in Michigan was ordered to close due to contamination. The plant was shut down in February following reports of illnesses in babies after consuming the company-made milk formulas, and two infants have died.
“The FDA is continuing to work diligently to ensure the safe resumption of production of infant formula at Abbott Nutrition’s Sturgis, Michigan, facility,” the USFDA commented with regards to Abbot’s plant reopening. “The agency expects that the measures and steps it is taking, and the potential for Abbott Nutrition’s Sturgis, Michigan, facility, to safely resume production in the near-term, will mean more and more infant formula is either on the way to or already on store shelves moving forward.”
